Slingshot members are tracking this event:

Ionis Pharma (IONS) to report on Phase 3 study of IONIS-SMN Rx in Infants with Spinal Muscular Atrophy in the summer of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details ISIS-SMNRx is designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein.  

The United States Food and Drug Administration granted orphan drug status and fast track designation to ISIS-SMNRx for the treatment of patients with SMA.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 24, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Sma, Spinal Muscular Atrophy, Muscular Dystrophy, Phase 3 Study, Ionis-smn Rx, Isis 396443